_:n470435377e4344e1bfc639e7ee5b9d80xb0
<http://schema.org/description>
"Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1Read the full statement from Cyclo Therapeutics here:Here is a summary of the article: • Landmark Milestone: Cyclo Therapeutics has completed enrollment for their Phase 3 TransportNPC™ trial, which is a pivotal study for treating Niemann-Pick Disease Type C1 (NPC1). • Study Details: The study enrolled 104 patients globally and includes a subst"
<https://www.npcd.org.au/post/cyclo-therapeutics-media-release-may-30-2024>